Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives
dc.contributor.author | Gómez Aguado, Itziar | |
dc.contributor.author | Rodríguez Castejón, Julen | |
dc.contributor.author | Vicente Pascual, Mónica | |
dc.contributor.author | Rodríguez Gascón, Alicia | |
dc.contributor.author | Solinís Aspiazu, María Ángeles | |
dc.contributor.author | Del Pozo Rodríguez, Ana | |
dc.date.accessioned | 2020-03-03T17:17:00Z | |
dc.date.available | 2020-03-03T17:17:00Z | |
dc.date.issued | 2020-02-20 | |
dc.identifier.citation | Nanomaterials 10(2) : (2020) // Article ID 364 | es_ES |
dc.identifier.issn | 2079-4991 | |
dc.identifier.uri | http://hdl.handle.net/10810/41920 | |
dc.description.abstract | The use of messenger RNA (mRNA) in gene therapy is increasing in recent years, due to its unique features compared to plasmid DNA: Transient expression, no need to enter into the nucleus and no risk of insertional mutagenesis. Nevertheless, the clinical application of mRNA as a therapeutic tool is limited by its instability and ability to activate immune responses; hence, mRNA chemical modifications together with the design of suitable vehicles result essential. This manuscript includes a revision of the strategies employed to enhance in vitro transcribed (IVT) mRNA functionality and efficacy, including the optimization of its stability and translational efficiency, as well as the regulation of its immunostimulatory properties. An overview of the nanosystems designed to protect the mRNA and to overcome the intra and extracellular barriers for successful delivery is also included. Finally, the present and future applications of mRNA nanomedicines for immunization against infectious diseases and cancer, protein replacement, gene editing, and regenerative medicine are highlighted. | es_ES |
dc.description.sponsorship | This research was funded by the MCIU/AEI/FEDER, UE (RTI2018-098672-B-I00), and by the UPV/EHU (GIU17/032). | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | MDPI | es_ES |
dc.relation | info:eu-repo/grantAgreement/MINECO/RTI2018-098672-B-I00 | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | |
dc.subject | in vitro transcribed messenger RNA (IVT mRNA) | es_ES |
dc.subject | gene therapy | es_ES |
dc.subject | nanomedicine | es_ES |
dc.subject | immunotherapy | es_ES |
dc.subject | infectious disease vaccines | es_ES |
dc.subject | cancer immunotherapy | es_ES |
dc.subject | Chimeric Antigen Receptor (CAR) T cells | es_ES |
dc.subject | dendritic cells | es_ES |
dc.subject | protein replacement | es_ES |
dc.subject | gene editing | es_ES |
dc.title | Nanomedicines to Deliver mRNA: State of the Art and Future Perspectives | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.date.updated | 2020-03-02T12:41:05Z | |
dc.rights.holder | © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). | es_ES |
dc.relation.publisherversion | https://www.mdpi.com/2079-4991/10/2/364/htm | es_ES |
dc.identifier.doi | 10.3390/nano10020364 | |
dc.departamentoes | Farmacia y ciencias de los alimentos | es_ES |
dc.departamentoeu | Farmazia eta elikagaien zientziak | es_ES |
Files in this item
This item appears in the following Collection(s)
Except where otherwise noted, this item's license is described as © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).